protagonist12 Thursday, 08/25/16 02:45:37 PM Re: None Post # of 28 Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets acted as lead managers on the deal.